Article

Novartis presents latest data on verteporfin for AMD

Researchers working with Novartis Ophthalmics presented data Monday onwet age-related macular degeneration (AMD) and verteporfin (Visudyne) therapyduring a session on AMD.Entitled "Age-Related Macular Degeneration: Photodynamic Therapy,"the session highlighted three papers that focused on verteporfin.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions
(Image credit: Ophthalmology Times) Introducing iOpeners: Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
Related Content
A study of the progression of sensitivity loss in GA over time using inferred data
August 30th 2025

A study of the progression of sensitivity loss in GA over time using inferred data

3 Things You Should Know About the GA Pipeline
August 30th 2025

NK Insights: An Interactive Corneal Sensitivity Testing Workshop

FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010
August 30th 2025

FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010

3 Things You Should Know About the GA Pipeline
August 30th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/racesy) Q&A: Inside the CCOI Myopia Workshop with Assoc Prof Daniel Ting
August 30th 2025

Q&A: Inside the CCOI Myopia Workshop with Assoc Prof Daniel Ting

Study finds value in home OCT monitoring
August 30th 2025

Study finds value in home OCT monitoring

© 2025 MJH Life Sciences

All rights reserved.